Biotechnology - Biotechnology, Biogen Idec

Filter

Current filters:

BiotechnologyBiogen Idec

Popular Filters

1 to 25 of 91 results

Biogen Idec and SOBI’s Elocta MAA validated in Europe

01-11-2014

Biotechnology companies Biogen Idec of the USA and Swedish Orphan Biovitrum said on Friday that the European…

Biogen IdecBiotechnologyEloctaEloctateEuropeHematologyRegulationSwedish Orphan Biovitrum

Biogen Idec third-qtr net rockets 76% but shares slump

Biogen Idec third-qtr net rockets 76% but shares slump

23-10-2014

US biotech firm Biogen Idec saw its share price plunge 7% to $303.51, after its posted third-quarter…

Biogen IdecBiotechnologyFinancialNeurologicalTecfideraUSA

Biogen Idec files for Elocta approval in Europe

Biogen Idec files for Elocta approval in Europe

10-10-2014

US biotech firm Biogen Idec has submitted a Marketing Authorization Application (MAA) for Elocta (rFVIIIFc;…

Biogen IdecBiotechnologyEloctaEloctateEuropeHematologyRegulationSwedish Orphan Biovitrum

Swedish Orphan Biovitrum adds new molecule to its hemophilia collaboration with Biogen Idec

Swedish Orphan Biovitrum adds new molecule to its hemophilia collaboration with Biogen Idec

19-09-2014

Nordic biotech firm Swedish Orphan Biovitrum has added the preclinical fusion molecule rFVIIIFc-XTEN-vWF…

Biogen IdecBiotechnologyHematologyLicensingSobiSweden

Biogen Idec's Plegridy achieves positive results over two years in multiple sclerosis

Biogen Idec's Plegridy achieves positive results over two years in multiple sclerosis

12-09-2014

US biotech firm Biogen Idec has reported data confirming its Plegridy gives provides treatment effects…

Biogen IdecBiotechnologyNeurologicalPlegridyResearchUSA

Strong and sustained efficacy reported for Tecfidera over five years

Strong and sustained efficacy reported for Tecfidera over five years

12-09-2014

Results from a five-year study with US biotech firm Biogen Idec’s Tecfidera show strong and sustained…

Biogen IdecBiotechnologyNeurologicalResearchTecfideraUSA

NICE recommends Biogen Idec’s Tecfidera for multiple sclerosis

NICE recommends Biogen Idec’s Tecfidera for multiple sclerosis

27-08-2014

The UK’s drugs watch dog, the National Institute for Health and Care Excellence (NICE), has recommended…

Biogen IdecBiotechnologyCNS DiseasesMultiple sclerosisRegulationTecfideraUK

Health Canada OKs Biogen Idec’s hemophilia A therapy Eloctate

Health Canada OKs Biogen Idec’s hemophilia A therapy Eloctate

26-08-2014

Canadian regulator Health Canada has approved US Biotech major Biogen Idec’s Eloctate (antihemophilic…

Biogen IdecBiotechnologyCanadaEloctateHematologyRegulationSwedish Orphan Biovitrum

Biogen Idec’s Plegridy gains US approval for multiple sclerosis

Biogen Idec’s Plegridy gains US approval for multiple sclerosis

17-08-2014

The US Food and Drug Administration has approved US biotech firm Biogen Idec’s (Nasdaq: BIIB) Plegridy…

Biogen IdecBiotechnologyNeurologicalPlegridyRegulationUSA

IQWiG finds no added benefit for Biogen Idec’s Tecfidera

IQWiG finds no added benefit for Biogen Idec’s Tecfidera

08-08-2014

In its early benefit assessment, the German Institute for Quality and Efficiency in Health Care (IQWiG)…

Biogen IdecBiotechnologyGermanyMSNeurologicalPricingRegulationTecfidera

Regulus shares up on deal with Biogen for microRNA biomarkers in MS

Regulus shares up on deal with Biogen for microRNA biomarkers in MS

05-08-2014

Regulus Therapeutics has entered into a new collaboration agreement with fellow US biotech firm Biogen…

Biogen IdecBiotechnologyMultiple sclerosisNeurologicalRegulus TherapeuticsResearchUSA

Biogen Idec’s 2nd-qtr 40% revenues growth beats forecasts

Biogen Idec’s 2nd-qtr 40% revenues growth beats forecasts

23-07-2014

Shares of US biotech firm Biogen Idec jumped 7.35% to $326 in pre-market trading today, as the company…

AlprolixBiogen IdecBiotechnologyElocateFinancialImmunologyPharmacologyTecfideraUSA

NICE issues positive draft FAD guidance on Tecfidera

NICE issues positive draft FAD guidance on Tecfidera

11-07-2014

UK health care cost watchdog the National Institute for Health and Care Excellence (NICE) has issued…

Biogen IdecBiotechnologyMultiple sclerosisNeurologicalPricingRegulationTecfideraUK

Isis Pharma earns $10 million milestone from Biogen

Isis Pharma earns $10 million milestone from Biogen

17-06-2014

Isis Pharmaceuticals revealed today it has earned a $10 million milestone payment from fellow US biotech…

Biogen IdecBiotechnologyFinancialIsis PharmaceuticalsNeurologicalResearch

Biogen Idec’s Eloctate gains FDA approval

Biogen Idec’s Eloctate gains FDA approval

09-06-2014

The US Food and Drug Administration on Friday approved US biotech firm Biogen Idec’s Eloctate, antihemophilic…

Biogen IdecBiotechnologyEloctateHematologyRegulationSwedish Orphan BiovitrumUSA

Array BioPharma inks deal with Biogen Idec on autoimmune disorders

Array BioPharma inks deal with Biogen Idec on autoimmune disorders

30-05-2014

US biotech firms Array BioPharma and Biogen Idec have entered into a collaboration for the discovery…

Array BioPharmaBiogen IdecBiotechnologyImmunologicalsLicensingResearch

Positive CHMP opinion for Biogen Idec MS drug Plegridy

25-05-2014

US biotech firm Biogen Idec said on Friday that it had received a positive recommendation from the European…

Biogen IdecBiotechnologyEuropeNeurologicalPlegridyRegulation

AAN 2014: Biogen Idec releases new trial data for peginterferon in MS

AAN 2014: Biogen Idec releases new trial data for peginterferon in MS

02-05-2014

US biotech firm Biogen Idec has released new two-year data from the Phase III ADVANCE clinical trial…

Biogen IdecBiotechnologyCytokinesHealth Medical PharmaHealth Medical PharmaImmune systemImmunologyNeurologicalpeginterferon beta-1aResearchUSA

Biogen Idec 1st-qtr 2014 revenue leaps 51%, driven by Tecfidera and MS franchise

23-04-2014

US biotech firm Biogen Idec first-quarter 2014 results today, including revenue of $2.1 billion, a 51%…

Biogen IdecBiotechnologyFinancialNeurologicalResearchTecfidera

Biogen Idec exercises option for Amunix’ XTENylated Factor VIII

21-04-2014

US privately-held biotech firm Amunix Operating says that Biogen Idec has exercised its option to enter…

AmunixBiogen IdecBiotechnologyHematologyLicensing

US FDA clears Biogen Idec and SOBI’s Alprolix for hemophilia B

US FDA clears Biogen Idec and SOBI’s Alprolix for hemophilia B

31-03-2014

Marking a second regulatory hurdle for the breakthrough product, the US Food and Drug Administration…

AlprolixBenefixBiogen IdecBiotechnologyCSL LimitedHematologyNorth AmericaNovo NordiskPfizerRegulationSwedish Orphan BiovitrumUSA

FDA delays approval of Biogen Idec’s MS drug Plegridy

FDA delays approval of Biogen Idec’s MS drug Plegridy

18-03-2014

The US Food and Drug Administration has extended the initial Prescription Drug User Fee Act date for…

Biogen IdecBiotechnologyNeurologicalNorth AmericaPlegridyRegulationUSA

Australian regulator finds no definite melanoma link for natalizumab

Australian regulator finds no definite melanoma link for natalizumab

18-03-2014

Australia’s Therapeutic Goods Administration revealed today that it is monitoring reports of melanoma…

Asia-PacificAustraliaBiogen IdecBiotechnologyNatalizumabNeurologicalRegulationTysabri

1 to 25 of 91 results

Back to top